Role of the nuclear matrix proteins in malignant transformation and cancer diagnosis

Experimental Oncology

Volumn 26, Issue 3, 2004, Pages 170-178

  Sjakste, Nikolajs ^a   Sjakste, Tatjana ^a   Vikmanis, Uldis ^a  

^a UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Bladder cancer; Breast cancer; Colon cancer; Inherited cancer syndromes; Leukemias; Nuclear matrix proteins; Prostate cancer

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); NUCLEAR MATRIX PROTEIN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; ENZYME; LAMIN; RNA;

APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CARCINOGENESIS; COLON CANCER; FAMILIAL CANCER; GENE MUTATION; HUMAN; LEUKEMIA; MALIGNANT TRANSFORMATION; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE C MYC; PATHOGENESIS; PHENOTYPE; PROSTATE CANCER; PROTEIN ANALYSIS; REVIEW; SOLID TUMOR; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; ARTICLE; CANCER CLASSIFICATION; CELL NUCLEUS; CELL TRANSFORMATION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; GENE REPLICATION; GENETIC CODE; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY;

BREAST NEOPLASMS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; NUCLEAR MATRIX-ASSOCIATED PROTEINS; ONCOGENES; TUMOR MARKERS, BIOLOGICAL; UROGENITAL NEOPLASMS;

EID: 7044253006     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Alberti I, Barboro P, Barbesino M, Sanna P, Pisciotta L, Parodi S, Nicolo G, Boccardo F, Galli S, Patrone E, Balbi C. Changes in the expression of cytokeratins and NMP are correlated with the level of differentiation in human prostate cancer. J Cell Biochem 2000; 79: 471-85.
2. Alberti I, Parodi S, Barboro P, Sanna P, Nicolo G, Allera C, Patrone E, Galli S, Balbi C. Differential NM-intermediate filament expression in human prostate cancer in respect to benign prostatic hyperplasia. Cancer Lett 1996; 109: 193-8.
3. Arber DA, Chang KL, Lyda MH, Bedell V, Spielberger R, Slovak ML. Detection of NPM/MLF1 fusion in t(3; 5)-positive acute myeloid leukemia and myelodysplasia. Hum Pathol 2003; 34: 809-13.
4. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995; 1: 1295-300.
5. Bazarnova TM, Buldyaeva TV, Filatova LS, Akopov SB, Zbarsky IB. Phosphorylation and biosynthesis of high molecular weight proteins of tumor nuclear matrix. Cell Res 1998; 8: 195-207.
6. Ben-Yehoyada M, Ben-Dor I, Shaul Y. c-Abl tyrosine kinase selectively regulates p73 NM association. J Biol Chem 2003; 278: 34475-82.
7. Berney DM, Shamash J, Gaffney J, Jordan S, Oliver RT. DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer 2002; 87: 624-9.
8. Bidwell JP, Fey EG, van Wijnen AJ, Penman S, Stein JL, Lian JB, Stein GS. NMP distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res 1994; 54: 28-32.
9. Bildrici K, Tel N, Ozalp SS, Yalcin OT, Yilmaz V. Prognostic significance of DNA topoisomerase II alpha (Ki-S1) immunoexpression in endometrial carcinoma. Eur J Gynaecol Oncol 2002; 23: 540-4.
10. Boccardo F, Rubagotti A, Carmignani G, Romagnoli A, Nicolo G, Barboro P, Parodi S, Patrone E, Balbi C. Nuclear matrix proteins changes in cancerous prostate tissues and theirprognostic value in clinically localized prostate cancer. Prostate 2003; 55: 259-64.
11. Bredel M, Piribauer M, Marosi C, Birner P, Gatterbauer B, Fischer I, Strobel T, Rossler K, Budka H, Hainfellner JA. High expression of DNA topoisomerase II alpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur J Cancer 2002a; 38: 1343-7.
12. Bredel M, Pollack IF, Hamilton RL, Birner P, Hainfellner JA, Zentner J. DNA topoisomerase II alpha predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas. Int J Cancer 2002b; 99: 817-20.
13. Brunagel G, Shah U, Schoen RE, Getzenberg RH. Identification of calreticulin as a nuclear matrix proteins associated with human colon cancer. J Cell Biochem 2003; 89: 238-43.
14. Brunagel G, Schoen RE, Bauer AJ, Vietmeier BN, Getzenberg RH. Nuclear matrix proteins alterations associated with colon cancer metastasis to the liver. Clin Cancer Res 2002b; 8: 3039-45.
15. Brunagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix proteins alterations associated with human colon cancer. Cancer Res 2002a; 62: 2437-42.
16. Deppert W. Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions. J Cell Biochem 1996; 62: 172-80.
17. Deppert W. The NM as a target for viral and cellular oncogenes. Crit Rev Eukaryot Gene Expr 2000; 10: 45-61.
18. Di Carlo A, Terracciano D, Mariano A, Oliva A, D'Anniento M, Macchia V. Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors. Int J Oncol 2003; 23: 757-62.
19. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 2003; 4: 179-86.
20. Dingemans AC, van Ark-Otte J, Span S, Scagliotti GV, van der Valk P, Postmus PE, Giaccone G. Topoisomerase II alpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001; 32: 117-28.
21. Donat TL, Sakr W, Lehr JE, Pienta KJ. Unique NMP alterations in head and neck squamous cell carcinomas: intermediate biomarker candidates. Otolaryngol Head Neck Surg 1996; 114: 387-93.
22. Dong S, Qiu J, Stenoien DL, Brinkley WR, Mancini MA, Tweardy DJ. Essential role for the dimerization domain of NuMA-RARalpha in its oncogenic activities and localization to NuMA sites within the nucleus. Oncogene 2003; 22: 858-68.
23. Durfee T, Mancini MA, Jones D, Elledge SJ, Lee WH. The amino-terminal region of the retinoblastoma gene product binds a novel NMP that co-localizes to centers for RNA processing. J Cell Biol 1994; 127: 609-22.
24. Galande S. Chromatin (dis)organization and cancer: BUR-binding proteins as biomarkers for cancer. Curr Cancer Drug Targets 2002; 2: 157-90.
25. Genschel J, Schmidt HH. Mutations in the LMNA gene encoding lamin A/C. Hum Mutat 2000; 16: 451-9.
26. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, Bahnson RR. Bladder cancer-associated NM proteins. Cancer Res 1996; 56: 1690-4.
27. Getzenberg RH, Pienta KJ, Huang EY, Coffey DS. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 1991; 51: 6514-20.
28. Gotlieb WH, Goldberg I, Weisz B, Davidson B, Novikov I, Kopolovic J, Ben-Baruch G. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. Gynecol Oncol 2001; 82: 99-104.
29. Grobholz R, Zentgraf H, Kohrmann KU, Bleyl U. Bax, bcl-2, fas and Fas-L antigen expression in human seminoma: correlation with the apoptotic index. APMIS 2002; 110: 724-32.
30. Hair A, Razin SV, Vasetskii ES. Changes in chromatin organization during early development and carcinogenesis. Ontogenez 2002; 33: 85-9 (in Russian).
31. Hirano J, Wang X, Kita K, Higuchi Y, Nakanishi H, Uzawa K, Yokoe H, Tanzawa H, Yamaura A, Yamamori H, Nakajima N, Nishikiori C, Suzuki N. Low levels of nuclear matrix protein gene expression in UV-sensitive human cell lines. Cancer Lett 2000; 153: 183-8.
32. Huang JM, Lin TY, Chang D, Lin SL, Ying SY. Truncated bcl-2, a potential pre-metastatic marker in prostate cancer. Biochem Biophys Res Commun 2003; 306: 912-7.
33. Huang S, Rhee E, Patel H, Park E, Kaswick J. Urinary nuclear matrix protein 22 and renal cell carcinoma. Urology 2000; 55: 227-30.
34. Ishii T, Okadome A, Takeuchi F, Hiratsuka Y. Urinary levels of nuclear matrix protein 22 in patients with urinary diversion. Urology 2001; 58: 940-2.
35. Izzo RS, Pellecchia C. Comparison of nuclear matrix protein composition in colon cancer and dysplasia. Scand J Gastroenterol 1998, 33: 191-4.
36. Jarvinen TA, Liu ET. HER-2/neu and topoisomerase II alpha in breast cancer. Breast Cancer Res Treat 2003; 78: 299-311.
37. Jiang M, Axe T, Holgate R, Rubbi CP, Okorokov AL, Mee T, Milner J. p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress. Oncogene 2001; 20: 5449-58.
38. Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D'Andrea AD, Hua X. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 2003; 63: 4204-10.
39. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Survivin and bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004; 128: 39-43.
40. Keesee SK, Marchese J, Meneses A, Potz D, Garcia-Cuellar C, Szaro RP, Solorza G, Osornio-Vargas A, Mohar A, de la Garza JG, Wu YJ. Human cervical cancer-associated nuclear matrix proteins. Exp Cell Res 1998; 244: 14-25.
41. Keesee SK, Meneghini MD, Szaro RP, Wu YJ. Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci U S A 1994; 91: 1913-6.
42. Keesee SK, Meyer JL, Hutchinson ML, Cibas ES, Sheets EE, Marchese J, Oreper A, Potz D, Wu YJ. Preclinical feasibility study of nuclear matrix protein 179, a nuclear matrix protein marker for cervical dysplasia. Acta Cytol 1999; 43: 1015-22.
43. Khanuya PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, Pienta KJ. Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 1993; 53: 3394-8.
44. Klempnauer KH. Interaction of myb proteins with nuclear matrix in vitro. Oncogene 1988; 2: 545-51.
45. Klobusicka M, Kusenda J, Babusikova O. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients. Neoplasma 2002; 49: 387-93.
46. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, Getzenberg RH. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000a; 6: 2618-25.
47. Konety BR, Nguyen TS, Brenes G, Sholder A, Lewis N, Bastacky S, Potter DM, Getzenberg RH. Clinical usefulness of the novel marker BLCA-4 for the detection of bladdercancer. J Urol 2000b; 164: 634-9.
48. Konstantinidou AE, Patsouris E, Korkolopoulou P, Kavantzas N, Mahera H, Davaris P. DNA topoisomerase II alpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas. Histopathology 2001; 39: 402-8.
49. Korb J, Stokrova J, Karafiat V. Ultrastructural analysis of v-Myb oncogene product cooperation with components of avian cell nuclear matrix. Folia Biol (Praha) 2000; 46: 137-42.
50. Korkolopoulou P, Patsouris E, Konstantinidou AE, Christodoulou P, Thomas-Tsagli E, Kouzelis K, Angelidakis D, Rologis D, Davaris P. Mitosin and DNA topoisomerase II alpha: two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival. Appl Immunohistochem Mol Morphol 2001; 9: 207-14.
51. Korshunov A, Shishkina L, Golanov A. DNA topoisomerase II alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. Arch Pathol Lab Med 2002; 126: 1079-86.
52. Kuzmina SN, Buldyaeva TV, Akopov SB, Zbarsky IB. Protein patterns of the nuclear matrix in differently proliferating and malignant cells. Mol Cell Biochem 1984; 58: 183-6.
53. Lahme S, Bichler KH, Feil G, Krause S. Comparison of cytology and nuclear matrix protein 22 for the detection and follow-up of bladder cancer. Urol Int 2001; 66: 72-7.
54. Lakshmanan Y, Subong EN, Partin AW. Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage. J Urol 1998; 159: 1354-8.
55. 3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001; 193: 1361-71.
56. Lazaris AC, Kavantzas NG, Zorzos HS, Tsavaris NV, Davaris PS. Markers of drug resistance in relapsing colon cancer. J Cancer Res Clin Oncol 2002; 128: 114-8.
57. Lekili M, Sener E, Demir MA, Temeltas G, Muezzinoglu T, Buyuksu C. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Urol Res 2004; 32: 124-8.
58. Leman ES, Madigan MC, Brunagel G, Takaha N, Coffey DS, Getzenberg RH. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem 2003; 88: 599-608.
59. Li Z, Takeuchi S, Ohara N, Maruo T. Paradoxically abundant expression of bcl-2 and adrenomedullin in invasive cervical squamous carcinoma. Int J Clin Oncol 2003; 8: 83-9.
60. Mancini MA, Shan B, Nickerson JA, Penman S, Lee WH. The retinoblastoma gene product is a cell cycle-dependent, nuclear matrix-associated protein. Proc Natl Acad Sci USA 1994; 91: 418-22.
61. Meissner M, Lopato S, Gotzmann J, Sauermann G, Barta A. Proto-oncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR proteins. Exp Cell Res 2003; 283: 184-95.
62. Menendez V, Filella X, Alcover JA, Molina R, Mallafre JM, Ballesta AM, Talbot-Wright R. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder. Anticancer Res 2000; 20: 1169-72.
63. Meyers S, Hiebert SW. Alterations in subnuclear trafficking of nuclear regulatory factors in acute leukemia. J Cell Biochem Suppl 2000; 35: 93-8.
64. Nagy B, Tiszlavicz L, Eller J, Molnar J, Thurzo L. Ki-67, cyclin D1, p53 and bcl-2 expression in advanced head and neck cancer. In Vivo 2003; 17: 93-6.
65. Nahta R, Esteva FJ. Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol 2003; 30: 143-9.
66. Oehr P. Proteomics as a tool for detection of nuclear matrix protein and new biomarkers for screening of early tumors stage. Anticancer Res 2003; 23: 805-12.
67. Okorokov AL, Rubbi CP, Metcalfe S, Milner J. The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage. Oncogene 2002; 21: 356-67.
68. Ozaki T, Saijo M, Murakami K, Enomoto H, Taya Y, Sakiyama S. Complex formation between lamin A and the retinoblastoma gene product: identification of the domain on lamin A required for its interaction. Oncogene 1994; 9: 2649-53.
69. Ozer E, Canda MS, Ulukus C, Guray M, Erbayraktar S. Expression of bcl-2, bax and p53 proteins in pituitary adenomas: an immunohistochemical study. Tumori 2003; 89: 54-9.
70. Pan W, Ishii H, Ebihara Y, Gobe G. Prognostic use of growth characteristics of early gastric cancer and expression patterns of apoptotic, cell proliferation, and cell adhesion proteins. J Surg Oncol 2003; 82: 104-10.
71. Pannek J, Lakshmanan Y, Pound CR, Lemkin PF, Epstein JI, Partin AW. Nuclear shape and NMP composition in prostate and seminal vesicles. Urology 1999; 54: 934-9.
72. Parekattil SJ, Fisher HA, Kogan BA. Neural network using combined urine nuclear matrix protein 22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J Urol 2003; 169: 917-20.
73. Park SH, Suh YL. Expression of cyclin A and topoisomerase II alpha of oligodendrogliomas is correlated with tumour grade, MIB 1 labelling index and survival. Histopathology 2003; 42: 395-402
74. Partin AW, Briggman JV, Subong EN, Szaro R, Oreper A, Wiesbrock S, Meyer J, Coffey DS, Epstein JI. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO: 4-216) prepared from human prostate cancer nuclear matrix proteins. Urology 1997; 50: 800-8.
75. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, Coffey DS. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993; 53: 744-6.
76. Pattari SK, Dey P. Urine: beyond cytology for detection of malignancy. Diagn Cytopathol 2002; 27: 139-42.
77. Raziuddin A, Court D, Sarkar FH, Liu YL, Kung H, Raziuddin R. A c-erbB-2 promoter-specific nuclear matrix protein from human breast tumor tissues mediates NF-kappaB DNA binding activity. J Biol Chem 1997; 272: 15715-20.
78. Roessler K, Gatterbauer B, Kitz K. Topoisomerase II alpha as a reliable proliferation marker in meningiomas. Neurol Res 2002; 24: 241-3.
79. Reszec J, Sulkowska M, Famulski W, Guzinska-Ustymowicz K, Sulkowski S. The expression of tumorigenesis markers in oral papilloma. Pol J Pathol 2002; 53: 195-200.
80. Saeger W, Schreiber S, Ludecke DK. Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas. Endocr Pathol 2001; 12: 39-47.
81. Samuel SK, Minish TM, Davie JR. Nuclear matrix protein in well and poorly differentiated human breast cancer cell lines. J Cell Biochem 1997a; 66: 9-15.
82. Samuel SK, Minish TM, Davie JR. Altered nuclear matrix protein profiles in oncogene-transformed mouse fibroblasts exhibiting high metastatic potential. Cancer Res 1997b; 57: 147-51.
83. Sato S, Hasegawa M, Ihn H, Kikuchi K, Takehara K. Clinical significance of antinuclear matrix antibody in serum from patients with anti-UIRNP antibody. Arch Dermatol Res 2000; 292: 55-9.
84. Scopa CD, Tsamandas AC, Zolota V, Kalofonos HP, Batistatou A, Vagianos C. Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study. Dig Dis Sci 2003; 48: 1990-7.
85. Sjakste NI. Modification of the structure of chromatin and the nuclear matrix in pathological processes. Prospects for correction with drugs. Vopr Med Chem 1993; 39: 10-6 (In Russian).
86. Sjakste NI. Modification of the structure of chromatin and the nuclear matrix in cell malignant transformation and cancer treatment. Exp Oncol 1992; 14: 19-23 (In Russian).
87. Sjakste NI, Sjakste TG. Enzyme activities of nuclear matrix. Biochemistry (Moscow) 1994; 50: 1239-46.
88. Sjakste NI, Sjakste TG. Transcription factors and the nuclear matrix. Mol Biol 2001; 35: 627-35.
89. Sjakste NI, Sjakste TG. Specificity of the interaction of carcinogenic and cytostatic agents with the elements of the genome at different levels of its organization. Exp Oncol 1988; 10: 3-8 (In Russian).
90. Smith LM, Anderson JR, Coffin CM. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). Med Pediatr Oncol 2002; 38: 398-404.
91. Spencer VA, Samuel SK, Davie JR. Nuclear matrix proteins associated with DNA in situ in hormone-dependent and hormone-independent human breast cancer cell lines. Cancer Res 2000; 60: 288-92.
92. Spencer VA, Samuel SK, Davie JR. Altered profiles in nuclear matrix proteins associated with DNA in situ during progression of breast cancer cells. Cancer Res 2001; 61: 1362-6.
93. Struchkov VA, Strazhevskaya NB, Zhdanov RI. DNA-bound lipids of normal and tumor cells: retrospective and outlooks for functional genomics. Bioelectrochemistry 2002; 58: 23-30.
94. Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW. Monoclonal antibody to prostate cancer NMP (PRO: 4-216) recognizes nucleophosmin/B23. Prostate 1999; 39: 298-304.
95. Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol 2003; 29: 654-7.
96. Waitz W, Loidl P. Cell cycle dependent association of c-myc protein with the nuclear matrix. Oncogene 1991; 6: 29-35.
97. Wang ZH, Ding MX, Chew-Cheng SB, Yun JP, Chew EC. Bcl-2 and Bax proteins are NM associated proteins. Anticancer Res 1999; 19: 5445-9.
98. Watanuki A, Ohwada S, Fukusato T, Makita F, Yamada T, Kikuchi A, Morishita Y. Prognostic significance of DNA topoisomerase II alpha expression in human hepatocellular carcinoma. Anticancer Res 2002; 22: 1113-9.
99. Weidner N, Weinberg DS, Hardy SC, Hollister KA, Lidgard GP. Localization of nuclear matrix proteins (NMPs) in multiple tissue types with NM-200. 4 (an antibody strongly reactive with NMPs found in breast carcinoma). Am J Pathol 1991; 138: 1293-8.
100. Wilson CS, Medeiros LJ, Lai R, Butch AW, McCourty A, Kelly K, Brynes RK. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance. Mod Pathol 2001; 14: 886-91.
101. Wisecarver JL, Synovec MS, Pirrucello S, Linder J. Marking characteristics of anti-nuclear matrix protein NM 200. 4 in human breast carcinomas and normal human tissues. J Clin Lab Anal 1993; 7: 134-8.
102. Xiong XD, Li EM, Xu LY, Chen HB, Chen L, Cai WJ, Han YL, Shen ZY, Zeng Y. Separation and identification of differentially expressed nuclear matrix proteins between human esophageal immortalized and carcinomatous cell lines. World J Gastroenterol 2003; 9: 2143-8.
103. Yam HF, Wang ZH, Or PC, Wang SW, Li J, Chew EC. Effect of glucocorticoid hormone on nuclear matrix in cervical cancer cells in vitro. Anticancer Res 1998; 18: 209-16.
104. Yanagisawa J, Ando J, Nakayama J, Kohwi Y, Kohwi-Shigematsu T. A matrix attachment region (MAR)-binding activity due to a p114 kilodalton protein is found only in human breast carcinomas and not in normal and benign breast disease tissues. Cancer Res 1996; 56: 457-62.
105. Yu Y, Dong W, Li X, Yu E, Zhou X, Li S. Significance of c-Myc and bcl-2 protein expression in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003; 129: 1322-6.
106. Yu E, Lee I, Lee MJ, Jang JJ. Progressive changes of the nuclear matrix protein composition in diethylnitrosamine-induced rat hepatocarcinogenesis. Cancer Lett 1999; 138: 151-7.
107. Zagrodnik B, Kempf W, Seifert B, Muller B, Burg G, Urosevic M, Dummer R. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and bcl-2. Cancer 2003; 98: 2708-14.
108. Zbarsky IB. Nuclear skeleton structures in some normal and tumor cells. Mol Biol Rep 1981; 7: 139-48.
109. Zbarsky IB. On the history of nuclear matrix manifestation. Cell Res 1998; 8: 99-103.